Top Page
Wellnex Life Ltd
(Sydney:WNX)
Wellnex Life Ltd (WNX) vs. iShares MSCI Australia ETF (EWA)
Wellnex Life Ltd Business Overview & Revenue Model
Wellnex Life Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.58M | 23.63M | 16.93M | 27.89M | 18.61M | 1.20M |
| Gross Profit | 5.92M | 6.88M | -776.00K | 4.75M | 4.50M | -165.00K |
| EBITDA | -4.46M | -6.62M | -10.57M | -6.82M | -6.35M | -18.41M |
| Net Income | -9.87M | -15.60M | -13.74M | -13.85M | -7.45M | -24.69M |
Balance Sheet | ||||||
| Total Assets | 27.83M | 27.84M | 30.92M | 15.04M | 19.61M | 10.42M |
| Cash, Cash Equivalents and Short-Term Investments | 975.00K | 497.00K | 903.00K | 322.00K | 3.18M | 7.78M |
| Total Debt | 10.03M | 5.45M | 10.67M | 6.95M | 7.86M | 9.31M |
| Total Liabilities | 17.78M | 16.59M | 24.86M | 14.45M | 15.25M | 10.67M |
| Stockholders Equity | 10.04M | 11.25M | 6.06M | 594.00K | 4.36M | -249.00K |
Cash Flow | ||||||
| Free Cash Flow | -1.41M | -666.00K | -6.82M | -6.19M | -8.65M | -5.17M |
| Operating Cash Flow | -1.41M | -666.00K | -6.82M | -6.19M | -8.61M | -4.38M |
| Investing Cash Flow | -8.07M | -8.29M | -13.42M | -2.20M | -3.65M | 9.45M |
| Financing Cash Flow | 10.18M | 8.55M | 20.82M | 5.53M | 7.66M | 1.55M |
Wellnex Life Ltd Technical Analysis
Wellnex Life Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
43 Neutral | AU$6.66M | -0.26 | ― | ― | -21.84% | 79.99% | |
42 Neutral | AU$7.00M | -0.92 | -184.71% | ― | 39.53% | 49.99% | |
41 Neutral | AU$5.70M | -1.62 | -60.84% | ― | -18.70% | 20.83% | |
41 Neutral | AU$19.60M | -2.06 | -29.43% | ― | 102.21% | 69.47% | |
41 Neutral | AU$25.75M | -33.08 | ― | ― | 6.76% | ― |
Wellnex Life Ltd Corporate Events
Wellnex Life Ltd has confirmed the cessation of 146,316 listed options (WNXAB), which expired on 6 February 2026 with an exercise price of $7.50 and lapsed without being exercised or converted. The expiration slightly reduces the company’s potential future share dilution from this series of options, clarifying its issued capital structure for investors and simplifying its securities on issue.
The notification, lodged as an Appendix 3H with the ASX, formally records the removal of these options from Wellnex Life’s capital base and updates the market on the change. While there is no immediate cash inflow from the unexercised options, the move provides greater transparency for stakeholders assessing the company’s equity position and potential overhang from derivative securities.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.10 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Ltd has notified the market of the issue of 1,732,283 unquoted options exercisable at $0.65 and expiring on 27 February 2029. The options, issued on 27 February 2026, form part of the company’s unquoted equity securities and signal the ongoing use of options as a tool for funding, incentive alignment or capital management, with potential future dilution for existing shareholders depending on exercise.
The move underscores Wellnex Life’s continued reliance on equity-based instruments in its capital structure, which may support growth initiatives or reward key stakeholders without immediate cash outlay. While the options are unquoted and therefore not directly tradable on the ASX, their terms set a clear price and time frame that could influence future share capital composition and investor expectations around potential share issuance.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.10 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life reported half-year revenue of $12.9 million for the period ended 31 December 2025, an 8% increase on the prior corresponding period, with brand sales contributing 72.3% and the remainder from IP licensing. The loss after tax narrowed sharply to $1.8 million, down 76.2% from a year earlier, while no dividends were declared.
The company has embarked on a strategic turnaround aimed at creating a leaner, more agile operating model, including tighter management and capital discipline. This program has lifted gross margin to 32.1%, up 9.4 percentage points, and saw the group close the second quarter of FY26 at operating breakeven, providing a platform for targeted revenue growth and more consistent performance in the second half.
Net tangible assets per share remained negative at 13.06 cents, slightly worse than the prior period’s 12.51 cents, highlighting a still-stretched balance sheet despite operational improvements. The half-year financial statements were reviewed by the company’s auditors, and Wellnex Life continues to position its turnaround as a pathway to long-term value creation for shareholders.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.11 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life has received unsolicited preliminary interest from separate parties in acquiring its Pain Away brand and other assets, with early-stage due diligence now underway. The company has also been approached by a syndicate with an indicative proposal for convertible note funding aimed at supporting Pain Away’s expansion into Asia and North America.
The board is evaluating these approaches alongside traditional debt and equity options to determine an optimal capital structure that supports its turnaround, settles former director loan repayments due in April 2026, and maximises shareholder value. Wellnex cautions that there is no certainty any of the potential transactions will proceed or on what terms, and says any deal will be assessed against regulatory requirements and announced in line with disclosure rules.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life reported a sharp improvement in operating cash flow in the December 2025 quarter, with net operating cash outflow reduced to $0.16 million from $2.98 million in the prior quarter, supported by a 31.5% quarter-on-quarter rise in total revenue to $7.1 million and stronger customer cash receipts of $5.1 million. The result was driven by a 1000% surge in IP licensing revenue to $3.3 million and ongoing strength in the Pain Away brand, partially offset by a 25.5% decline in branded product sales following a deliberate move to consolidate and deprioritise non-core assets; the company ended the quarter with $0.98 million in cash and $2.01 million in undrawn facilities and reaffirmed its focus on turnaround efforts, better cash conversion, margin enhancement and cost reduction.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life has reported a significant operational turnaround for the first half of FY26, with EBITDA improving by $2.4 million year-on-year and group gross margin rising from 22.8% to 31.3%, enabling the business to reach breakeven by the end of the second quarter. The Pain Away brand continued to gain traction, delivering $3.3 million in quarterly sales, expanding margins by 7.6%, and outpacing category growth in heat patches and roll-ons, supported by new product launches and expanded distribution through Priceline, major pharmacy wholesalers, and upcoming Costco trials, positioning the company for more stable and sustainable performance into the second half of the year.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life has disclosed that an Appendix 3Y notice was lodged late due to an administrative oversight during the Christmas–New Year period, while affirming that it understands its ASX disclosure obligations and has processes in place to ensure timely future filings. The company also detailed off-market internal share transfers within entities associated with Homart Group, involving a total of 1,285,409 Wellnex Life shares moved from Homart Group to JYSF Management Pty Ltd and MYLY Management Pty Ltd, and confirmed that Homart Group Pty Ltd and MYLY Management Pty Ltd now have independent boards and are no longer associated with director Jeffrey Yeh, meaning these entities will act independently regarding their Wellnex Life holdings and upcoming ASIC filings will formalise this change in association status.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has announced the cessation of 1.4 million listed options (ASX code WNXAN), which carried an exercise price of $2.50 and expired on 1 January 2026 without being exercised or converted. The expiry of these options reduces the company’s potential future share dilution, effectively simplifying its capital structure and removing a class of derivative securities from its issued capital, with no immediate cash inflow resulting from option exercise.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Ltd has reported positive initial results from its turnaround strategy, focusing on scaling up the Pain Away brand and enhancing contract manufacturing revenues. The company achieved an EBITDA profit of $0.1 million in November, with year-to-date improvements in sales growth and gross margins. The introduction of Pain Away into major retailers like Costco and 7Eleven has boosted sales by 16%, and the company is on track to reach breakeven by Q2 FY2026. The board remains optimistic about further margin improvements and cost reductions in the upcoming quarters.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.